HBsAg Variant Detection via Segmented Oligopeptide Sequences
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and characterizing hepatitis B virus (HBV) variants and mutants, particularly those with amino acid substitutions in the 'a' determinant region, face challenges in precision due to high mutation rates and selection pressure from immunization and antiviral therapy, leading to diagnostic inaccuracies and the emergence of replication-capable escape mutants.
Innovation Solution
Development of novel oligopeptide and polypeptide sequences with specific amino acid substitutions, such as the HDB 11 variant, which allows for improved detection and differentiation of HBV variants using immunochemical methods and nucleic acid tests, including PCR, and the use of these sequences in vaccine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used for HBV variants, then detection can be performed with existing tools, but measurement precision deteriorates due to high mutation rates and amino acid substitutions in the 'a' determinant region
Solution Approach 1:
The patent segments the HBV detection approach by creating multiple detection systems targeting different regions: (1) nucleic acid detection using PCR with primers targeting conserved regions, and (2) immunochemical detection using antibodies against the 'a' determinant and other regions. This segmentation allows each method to compensate for the limitations of the other in detecting variants with amino acid substitutions.
Solution Approach 2:
The patent develops universal detection methods that can identify multiple HBV genotypes and subtypes simultaneously. The nucleic acid detection system uses conserved region primers that work across variants, while the immunochemical system uses antibodies that recognize conserved epitopes, enabling a single detection platform to handle diverse HBV variants without requiring variant-specific customization.
2Reliability
If selection pressure from immunization and antiviral therapy is applied, then control of HBV infection is improved, but harmful factors increase due to the emergence of replication-capable escape mutants
Solution Approach 1:
The patent employs preliminary action by using combination therapy approaches where multiple antiviral agents with different mechanisms of action are used simultaneously. This preliminary multi-pronged attack prevents the virus from developing resistance to any single agent, as escape mutants would need to acquire multiple resistance mutations simultaneously, which is statistically improbable.
Solution Approach 2:
The patent implements feedback mechanisms through rigorous monitoring and characterization of HBV variants during treatment. By continuously detecting and analyzing amino acid substitutions in the 'a' determinant and other regions, the system provides feedback on emerging resistance patterns, allowing clinicians to adjust treatment strategies before escape mutants become dominant.
3Adaptability or versatility
If detection methods are expanded to cover all HBV variants, then adaptability improves, but device complexity increases due to the need for multiple detection systems
Solution Approach 1:
The patent merges multiple detection capabilities into integrated diagnostic systems. The nucleic acid detection and immunochemical detection methods are designed to be used in combination, with each method complementing the other. This merging allows a single diagnostic workflow to detect both wild-type and variant HBV strains without requiring separate specialized tests for each variant type.
Data Source
AI summary
The invention relates to sequences of a novel variant of the Hepatitis B surface antigen (HBsAg) and to methods for detecting, in patient samples, nucleic acids, antigens, and antibodies directed against the same.